Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2022-02-07 00:00:00 ET · period of report 2022-02-03 · accession 0001714899-22-000024 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-07 | 2022-02-03 | DNLI | Harris Erik | Dir | A - Grant | $0.00 | +6,869 | 6,869 | New | $0 |
| D | 2022-02-07 | 2022-02-03 | DNLI | Harris Erik | Dir | A - Grant | $0.00 | +20.6K | 20.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-03 | A | A | 6,869 | $0.00 | 6,869 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. |
| 2 | Derivative | Stock Option (right to buy) | 2022-02-03 | A | A | 20,607 | $0.00 | 20,607 | D | $33.74 · — to 2032-02-03 | 20,607 Common Stock | (F3) 25% of the shares subject to the option shall vest on February 3, 2023, and an additional 1/48 of the shares subject to the option vest each month thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date |